{
    "ticker": "BKKLY",
    "name": "Brooklyn ImmunoTherapeutics, Inc.",
    "description": "Brooklyn ImmunoTherapeutics, Inc. is a biotechnology company focused on developing innovative immunotherapies for the treatment of cancer and other serious diseases. Established in 2017 and headquartered in Brooklyn, New York, the company is dedicated to advancing the field of immuno-oncology through its proprietary platform technologies. Brooklyn ImmunoTherapeutics is primarily engaged in the development of novel products that harness the power of the immune system to fight cancer. Their lead product candidate, BK008, is designed to enhance the anti-tumor immune response in patients with solid tumors. The company is committed to improving patient outcomes by utilizing cutting-edge science and technology in the development of its therapeutics. With a growing pipeline of immunotherapy candidates, Brooklyn ImmunoTherapeutics aims to address significant unmet medical needs in oncology and improve the quality of life for cancer patients. The company's mission is to deliver transformative therapies that can potentially change the standard of care in cancer treatment and ultimately make a difference in patients' lives.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Brooklyn, New York, USA",
    "founded": "2017",
    "website": "https://www.brooklynimmuno.com",
    "ceo": "Howard J. Safir",
    "social_media": {
        "twitter": "https://twitter.com/BrooklynImmuno",
        "linkedin": "https://www.linkedin.com/company/brooklyn-immunotherapeutics"
    },
    "investor_relations": "https://www.brooklynimmuno.com/investors",
    "key_executives": [
        {
            "name": "Howard J. Safir",
            "position": "CEO"
        },
        {
            "name": "Wendy P. Smith",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Immunotherapy Products",
            "products": [
                "BK008"
            ]
        }
    ],
    "seo": {
        "meta_title": "Brooklyn ImmunoTherapeutics, Inc. | Innovative Cancer Immunotherapies",
        "meta_description": "Explore Brooklyn ImmunoTherapeutics, Inc., a pioneering biotech company focused on developing groundbreaking immunotherapies for cancer treatment.",
        "keywords": [
            "Brooklyn ImmunoTherapeutics",
            "Immunotherapy",
            "Cancer Treatment",
            "Biotechnology",
            "BK008"
        ]
    },
    "faq": [
        {
            "question": "What does Brooklyn ImmunoTherapeutics focus on?",
            "answer": "The company focuses on developing innovative immunotherapies for cancer and other serious diseases."
        },
        {
            "question": "Who is the CEO of Brooklyn ImmunoTherapeutics?",
            "answer": "Howard J. Safir is the CEO of Brooklyn ImmunoTherapeutics, Inc."
        },
        {
            "question": "Where is Brooklyn ImmunoTherapeutics headquartered?",
            "answer": "The company is headquartered in Brooklyn, New York, USA."
        },
        {
            "question": "What is Brooklyn ImmunoTherapeutics' lead product?",
            "answer": "The lead product candidate is BK008, aimed at enhancing the anti-tumor immune response."
        },
        {
            "question": "When was Brooklyn ImmunoTherapeutics founded?",
            "answer": "The company was founded in 2017."
        }
    ],
    "competitors": [
        "BMY",
        "JNJ",
        "NVS",
        "REGN"
    ],
    "related_stocks": [
        "AMGN",
        "VRTX",
        "GILD",
        "CELG"
    ]
}